Giá trị hấp thụ tiêu chuẩn của khối u nguyên phát (SUVmax) đo trên 18F-FDG PET/CT và các thành phần NSCLC hỗn hợp tiên đoán sự sống sót ở bệnh nhân ung thư phổi nhỏ tế bào phối hợp được phẫu thuật cắt bỏ
Tóm tắt
Ung thư phổi nhỏ tế bào phối hợp (c-SCLC) là một dạng hiếm và có những đặc điểm lâm sàng - bệnh lý độc đáo. Mục tiêu của nghiên cứu này là điều tra các thông số 18F-FDG PET/CT và các yếu tố lâm sàng - bệnh lý ảnh hưởng đến tiên lượng của c-SCLC.
Từ tháng 11 năm 2005 đến tháng 10 năm 2014, các mẫu khối u đã được phẫu thuật cắt bỏ từ các bệnh nhân c-SCLC đã được xem xét hồi cứu sau khi thực hiện xét nghiệm 18F-FDG PET/CT trước phẫu thuật. Giá trị hấp thụ tối đa đã chuẩn hóa (SUVmax), thể tích khối u chuyển hóa (MTV) và sự phân giải glucose tổng thể của tổn thương (TLG) đã được sử dụng để đánh giá các thông số chuyển hóa ở các khối u nguyên phát. Tỷ lệ sống sót được đánh giá bằng phương pháp Kaplan–Meier. Phân tích đơn biến và đa biến được sử dụng để đánh giá các yếu tố tiên lượng tiềm năng.
Có 31 bệnh nhân được đưa vào nghiên cứu, với tuổi trung bình là 62 (phạm vi: 35−79) năm. Thành phần hỗn hợp phổ biến nhất là ung thư tế bào vảy (SCC,
Các bệnh nhân c-SCLC được phẫu thuật cắt bỏ có tiên lượng tương đối tốt. Giai đoạn TNM là yếu tố quan trọng nhất ảnh hưởng đến sự tiến triển của bệnh ở c-SCLC đã phẫu thuật cắt bỏ. Giá trị SUVmax và các thành phần NSCLC hỗn hợp trong c-SCLC có ảnh hưởng đáng kể đến sự sống sót. Cả giá trị SUVmax cao và thành phần SCC hỗn hợp đều là các dự đoán kém cho bệnh nhân c-SCLC.
Từ khóa
#c-SCLC #SUVmax #TNM stage #prognosis #NSCLCTài liệu tham khảo
Albano D, Bosio G, Treglia G, Giubbini R, Bertagna F (2018) 18F-FDG PET/CT in solitary plasmacytoma: metabolic behavior and progression to multiple myeloma. Eur J Nucl Med Mol Imaging 45:77–84
Babakoohi S, Fu P, Yang M, Linden PA, Dowlati A (2013) Combined SCLC clinical and pathologic characteristics. Clin Lung Cancer 14:113–119
Bai L et al (2017) SUVmax of 18F-FDG PET/CT correlates to expression of major chemotherapy-related tumor markers and serum tumor markers in gastric adenocarcinoma patients. Oncol Rep 37:3433–3440
Bille A et al (2013) The prognostic significance of maximum standardized uptake value of primary tumor in surgically treated non-small-cell lung cancer patients: analysis of 413 cases. Clin Lung Cancer 14:149–156
Brunette LL et al (2018) Predictive value of FDG PET/CT to detect lymph node metastases in cervical cancer. Clin Nucl Med 43:793–801
Burger IA et al (2016) 18F-FDG PET/CT of non-small cell lung carcinoma under neoadjuvant chemotherapy: background-based adaptive-volume metrics outperform TLG and MTV in predicting histopathologic response. J Nucl Med 57:849–854
Chang H, Lee SJ, Lim J, Lee JS, Kim YJ, Lee WW (2019) Prognostic significance of metabolic parameters measured by (18)F-FDG PET/CT in limited-stage small-cell lung carcinoma. J Cancer Res Clin Oncol 145:1361–1367
Chon HJ et al (2019) The clinical implications of FDG-PET/CT differ according to histology in advanced gastric cancer. Gastric Cancer 22:113–122
Du S, Sun H, Gao S, Xin J, Lu Z (2019) Metabolic parameters with different thresholds for evaluating tumor recurrence and their correlations with hematological parameters in locally advanced squamous cell cervical carcinoma: an observational (18)F-FDG PET/CT study. Quant Imaging Med Surg 9:440–452
Fraire AE, Johnson EH, Yesner R, Zhang XB, Spjut HJ, Greenberg SD (1992) Prognostic significance of histopathologic subtype and stage in small cell lung cancer. Hum Pathol 23:520–528
Fushimi H et al (1996) Histologic changes in small cell lung carcinoma after treatment. Cancer 77:278–283
Ha SC et al (2017) Pretreatment tumor SUVmax predicts disease-specific and overall survival in patients with head and neck soft tissue sarcoma. Eur J Nucl Med Mol Imaging 44:33–40
Hage R, Elbers JR, de Brutel RA, van den Bosch JM (1998) Surgery for combined type small cell lung carcinoma. Thorax 53:450–453
Hasbek Z, Ozer H, Erturk SA, Erdiş E, Yucel B, Çiftçi E, Çakmakcilar A (2019) Relationships between hypoxia induced factor-1α and (18)F-FDG PET/CT parameters in colorectal cancer. Rev Esp Med Nucl Imagen Mol 38:355–361
Hsieh CE et al (2018) Pretreatment primary tumor and nodal SUVmax values on 18F-FDG PET/CT images predict prognosis in patients with salivary gland carcinoma. Clin Nucl Med 43:869–879
Hsu HH et al (2016) SUVmax and tumor size predict surgical outcome of synchronous multiple primary lung cancers. Medicine 95:0000000000002351
Kim H, Yoo IR, Boo SH, Park HL, Jh O, Kim SH (2018) Prognostic value of pre- and post-treatment FDG PET/CT parameters in small cell lung cancer patients. Nucl Med Mol Imaging 52:31–38
Kwon SH et al (2016) The Highest Metabolic Activity on FDG PET Is Associated With Overall Survival in Limited-Stage Small-Cell Lung Cancer. Medicine 95:0000000000002772
Lee HY et al (2015) Role of CT and PET imaging in predicting tumor recurrence and survival in patients with lung adenocarcinoma: a comparison with the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification of Lung Adenocarcinoma. J Thorac Oncol 10:1785–1794
Lee SJ, Chung MS, Shin SJ, Choi YY (2018) Correlation of tumor uptake on breast-specific gamma imaging and fluorodeoxyglucose PET/CT with molecular subtypes of breast cancer. Medicine 97:0000000000012840
Lemarignier C, Martineau A, Teixeira L, Vercellino L, Espié M, Merlet P, Groheux D (2017) Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and textural features assessed with (18)F-FDG PET in a large cohort of oestrogen receptor-positive breast cancer patients. Eur J Nucl Med Mol Imaging 44:1145–1154
Lu HY et al (2012) Mutation status of epidermal growth factor receptor and clinical features of patients with combined small cell lung cancer who received surgical treatment. Oncol Lett 3:1288–1292
McSorley ST, Khor BY, Tsang K, Colville D, Han S, Horgan PG, McMillan DC (2018) The relationship between (18) F-FDG-PETCT-derived markers of tumour metabolism and systemic inflammation in patients with recurrent disease following surgery for colorectal cancer. Colorectal Dis 20:407–415
Men Y et al (2016) Further understanding of an uncommon disease of combined small cell lung cancer: clinical features and prognostic factors of 114 cases. Chin J Cancer Res 28:486–494
Mirili C et al (2019) Prognostic significance of neutrophil/lymphocyte ratio (NLR) and correlation with PET-CT metabolic parameters in small cell lung cancer (SCLC). Int J Clin Oncol 24:168–178
Moon SW, Seo JH, Jeon HW, Moon MH (2019) Effect of histological subtype and treatment modalities on T1–2 N0–1 small cell lung cancer: a population-based study. Thorac Cancer 10:1229–1240
Nicholson SA et al (2002) Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol 26:1184–1197
Nicholson AG et al (2016) The International Association for the Study of Lung cancer lung cancer staging project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol 11:300–311
Ohashi T et al (2020) The importance of FDG-PET/CT parameters for the assessment of the immune status in advanced HNSCC. Auris Nasus Larynx 20:30022–30025
Okamoto I, Araki J, Suto R, Shimada M, Nakagawa K, Fukuoka M (2006a) EGFR mutation in gefitinib-responsive small-cell lung cancer. Ann Oncol 17:1028–1029
Pankowska V, Malkowski B, Wedrowski M, Wedrowska E, Roszkowski K (2019) FDG PET/CT as a survival prognostic factor in patients with advanced renal cell carcinoma. Clin Exp Med 19:143–148
Park SB et al (2014) Prognostic value of volumetric metabolic parameters measured by [18F]fluorodeoxyglucose-positron emission tomography/computed tomography in patients with small cell lung cancer. Cancer Imaging 14:1470–7330
Park S et al (2016) Correlation between semi-quantitative (18)F-FDG PET/CT Parameters and Ki-67 expression in small cell lung cancer. Nucl Med Mol Imaging 50:24–30
Stinchcombe TE (2017) Current treatments for surgically resectable, limited-stage, and extensive-stage small cell lung cancer. Oncologist 22:1510–1517
Takagi Y, Nakahara Y, Hosomi Y, Hishima T (2013) Small-cell lung cancer with a rare epidermal growth factor receptor gene mutation showing "wax-and-wane" transformation. BMC Cancer 13:1471–2407
Tatematsu A et al (2008) Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res 14:6092–6096
Travis WD (2014) The 2015 WHO classification of lung tumors. Pathologe 2:014–1974
Tsujikawa T et al (2017) (18)F-FDG PET radiomics approaches: comparing and clustering features in cervical cancer. Ann Nucl Med 31:678–685
Veronesi G, Bottoni E, Finocchiaro G, Alloisio M (2015) When is surgery indicated for small-cell lung cancer? Lung Cancer 90:582–589
Wang Y et al (2020) New insight on the correlation of metabolic status on (18)F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging 47:1127–1136
Yu X, Song X, Zhu L, Chen W, Dai D, Li X, Xu W (2017a) Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the diagnosis of newly found suspected malignant solitary pulmonary lesions in patients who have received curative treatment for colorectal cancer. Gastroenterol Res Pract 3458739:12
Yu X et al (2017b) Pretreatment metabolic parameters measured by 18F-FDG-PET to predict the outcome of first-line chemotherapy in extensive-stage small-cell lung cancer. Nucl Med Commun 38:193–200
Zakowski MF, Ladanyi M, Kris MG (2006) EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med 355:213–215
Zer A et al (2016) The Role of 18F-FDG PET/CT on staging and prognosis in patients with small cell lung. Cancer Eur Radiol 26:3155–3161
Zhang C, Yang H, Zhao H, Lang B, Yu X, Xiao P, Zhang X (2017) Clinical outcomes of surgically resected combined small cell lung cancer: a two-institutional experience. J Thorac Dis 9:151–158
Zhao X et al (2019) Surgical resection of SCLC: prognostic factors and the tumor microenvironment. J Thorac Oncol 14:914–923